| COMPOSITION | |
|---|---|
| Clotrimazole | 1% |
| Beclomethasone Dipropionate | 0.025% |
| CholineSalicylate Benzalkonium Chloride | 9% |
| Benzalkonium Chloride | 0.02% |
Clotrimazole Beclomethasone Dipropionate CholineSalicylate Benzalkonium Chloride
GUMOVIB
| SPECIFICATION | |
|---|---|
| FORM | OIL |
| PACKING | 10ML |
| PACKING TYPE | – |
| MRP | 48 |
DESCRIPTION
An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. [PubChem]
Beclomethasone dipropionate is a prodrug of the free form, beclomethasone (beclomethasone-17-monopropionate). An anti-inflammatory, synthetic corticosteroid, it is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma and allergic rhinitis (seasonal and perennial). Beclometasone dipropionate is also being investigated for oral treatment in mild-to-moderate Crohn’s disease of ileal or ileal-right colonic localisation and for “topical” use mild-to-moderate graft versus host disease. It is marketed under several brand names such as Qnasl (US) and Rivanase AQ (Canada).
SIDE EFFECTS
Symptoms of overdose include erythema, stinging, blistering, peeling, edema, pruritus, urticaria, burning, and general irritation of the skin, and cramps.
The acute toxicity of beclometasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclometasone dipropionate over a long period could lead to adrenal suppression.
INDICATION
For the local treatment of oropharyngeal candidiasis and vaginal yeast infections, also used in fungal infections of the skin such as ringworm, athlete’s foot, and jock itch.
Used in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn’s disease of ileal or ileal-right colonic localisation and for “topical” use mild-to-moderate graft versus host disease.